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A B S T R A C T
Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease 
(CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational 
studies and clinical trials have shown that sevelamer has pleiotropic effects, beyond 
hyperphosphataemia control, including actions on inflammation, oxidative stress, lipid 
profile and atherogenesis, vascular calcification, endothelial dysfunction and the reduction 
of several uremic toxins. This is the biological basis for its global effect on cardiovascular 
morbidity and mortality in patients with chronic kidney disease. This review focuses on 
these pleiotropic actions of sevelamer and their impact on cardiovascular health, with the 
experience published after more than ten years of clinical expertise.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
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used for the control of hyperphosphataemia in chronic kidney 
disease (CKD) (8). Its concomitant administration with food 
reduces the absorption of this ion. Regarding its composition, 
it contains multiple amines, separated by one carbon in the 
polymer skeleton, which are partially ionised in the intestine 
and interact with phosphorus molecules by means of hydro-
gen and ionic bonds. Therefore, dietary phosphorus is bound 
in the gastrointestinal tract, captured and eliminated through 
the intestine, thus reducing serum concentrations (9).
Besides reducing phosphorus absorption due to its capac-
ity to capture it in the intestine without added calcium, seve-
lamer is capable of modifying adaptive mechanisms, such as 
reducing fibroblast growth factor 23 (FGF23) or parathyroid 
hormone (PTH). Moreover, since it was first marketed, other 
effects of this molecule have been confirmed, which are 
known as pleiotropic effects. Reductions have been described 
in lipids (10), changes in bone structure (11), inflammation 
(12), oxidative stress (13), anaemia (14), as well as fetuin-A (15), 
among others. All these effects of sevelamer have been asso-
ciated with a reduction in vascular calcification, an improve-
ment of cardiovascular lesions and, therefore, a reduction in 
mortality (16).
The pleiotropic effects of sevelamer, as it is not absorbed, 
are due to the intestinal effect of this molecule. Its binding to 
bile salts and its capacity to capture other molecules in the 
intestine seem to have other beneficial effects. This effect 
simply reinforces the importance the intestine has in uremic 
patients and opens the possibility of new treatments where 
the intestine is the site of action in patients with CKD and 
related complications (17). In this review, we analyse the dif-
ferent effects published with sevelamer, avoiding a detailed 
analysis of its phosphate binding effect on the intestine 
(Figure 1).
Introduction
Patients with chronic kidney disease (CKD) show an import-
ant increase in cardiovascular morbidity and mortality com-
pared to the general population. (1). Between 40% and 75% of 
patients who start dialysis have a cardiovascular disease 
(CVD), which accounts for 44% of the deaths of these patients 
and constitutes the most important cause of total cardiovas-
cular morbidity and mortality, adjusted for age and gender 
(2,3). One of the unusual cardiovascular risk factors in these 
patients is altered mineral metabolism (4).
At present, phosphorus is considered an important ele-
ment which causes vascular damage in people with normal 
renal function, and particularly in patients with renal failure 
(5). Control of its absorption to prevent overload is a usual 
practice in patients with kidney disease, but doubts have been 
raised about its usefulness in other patients. Diet and the use 
of phosphate binders are ways in which this control is 
achieved (6).
There are different types of phosphate binders, but each 
shows distinguishing features, which may include advantages 
other than the already proven reduction in phosphorus 
absorption. Recently, the lower mortality of non-calcium ver-
sus calcium binders has been reported as non-calcium binders 
shown better survival results (7). These studies have awoken 
interest in these binders once more, mainly in sevelamer and 
lanthanum. In this review, we focus on the analysis of seve-
lamer. This molecule has been used in clinical practice for 
more than ten years, and many studies have shown its effects 
on patients with kidney disease. In both forms (carbonate and 
hydrochloride), sevelamer is a metal- and calcium-free 
non-absorbable phosphate binder or chelating agent that is 
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R E S U M E N
El sevelamer es un captor no cálcico de fósforo que se utiliza en la ERC avanzada y en diálisis 
para el control de la hiperfosforemia. Varios estudios experimentales, observacionales y ensayos 
clínicos han mostrado que el sevelamer tiene efectos pleiotrópicos, más allá del control de 
la hiperfosforemia, incluyendo acciones sobre la inflamación, el estrés oxidativo, el perfil 
lipídico y la aterogénesis, la calcificación vascular, la disfunción endotelial y la disminución 
de diversas toxinas urémicas, todo lo cual sería la base biológica de su efecto global sobre la 
morbilidad y la mortalidad cardiovascular en pacientes con enfermedad renal crónica. En 
esta revisión, se hace énfasis en estas acciones pleiotrópicas del sevelamer y su impacto en la 
salud cardiovascular, con la experiencia publicada después de más de 10 años de experiencia 
clínica. © 2015 Revista xxx EU. Publicado por Elsevier España, S.L.U. Este es un artículo 
de acceso abierto distribuido bajo los términos de la Licencia Creative Commons 
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the use of sevelamer hydrochloride reduces serum FGF23 
levels in dialysis patients, presumably through the inhibition 
of phosphate loading in the intestine. Serum FGF23 levels sig-
nificantly decreased after four weeks of treatment with seve-
lamer hydrochloride + CaCO3 from the pretreatment levels (p 
<0.05), while no changes were found in patients treated with 
CaCO3 (28) alone.
Oliveira et al. confirmed this effect of sevelamer on FGF23 
in patients with CKD. In a 6-week randomised study, the effect 
of two phosphorus chelating agents (calcium acetate and 
sevelamer) on PTH and FGF23 was studied in patients with 
stage 3 and 4 CKD. During treatment with both chelating 
agents, there was a progressive decrease in serum PTH and 
urinary phosphorus, but there were no changes in serum cal-
cium or serum phosphorus. Significant changes for FGF23 
were only observed in patients treated with sevelamer (29).
The reduction in FGF23 increases calcitriol by reducing 
24-hydroxylase activity and increasing 1D-hydroxylase activ-
ity. However, there have also been reports of a slight decrease 
in intestinal absorption of lipids and liposoluble vitamins, 
including vitamin D, derived from binding to bile acids (30).
The reduction in serum FGF23 levels with sevelamer has a 
beneficial effect on vascular endothelial function in patients 
with kidney disease as it improves vascular flow-mediated 
vasodilation, which is an endothelial damage marker. In addi-
tion, FGF23 correlates with asymmetric dimethylarginine 
(ADMA) and it is an endogenous inhibitor of the nitric oxide 
1. Sevelamer, bone and mineral metabolism, and FGF23
a) FGF23
Fibroblast growth factor 23 (FGF23) is a member of the fibro-
blast growth factor superfamily that displays phosphaturic 
action, inhibition of 1D-hydroxylase in the proximal tubules, 
and 24-hydroxylase activation (18,19), which is why vitamin 
D activity is reduced. FGF23 plays an important role on vita-
min D and phosphorus metabolism (20-22). In uremia, both 
metabolisms are altered.
Both in healthy subjects and patients with CKD, FGF23 is 
secreted by osteocytes and osteoblasts as a response to oral 
phosphate overload (19,23,24). In addition, it is known that 
serum FGF23 levels increase at the early stages of chronic 
kidney disease in an initial attempt to avoid phosphorus 
retention, which increases phosphaturia. With the progres-
sion of CKD, in very advanced stages, hyperphosphataemia 
appears despite increased levels of FGF23 and PTH. Although 
this aspect is still being researched, it seems that the FGF23 
receptor and its Klotho coreceptor are expressed in many cell 
types, including cardiomyocytes, vascular wall, kidneys, and 
parathyroid glands (25,26). Moreover, elevated FGF23 is asso-
ciated with the development of endothelial dysfunction and 
cardiac hypertrophy in patients with CKD (27).
Several recent studies have shown the capacity of seve-
lamer to decrease FGF23 thanks to its capacity to reduce phos-
phorus absorption in the intestine. Koiwa et al. proved that 
Figure 1 – Scheme of the effects attributed to sevelamer and their influence on survival in patwients with renal failure.
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iron supplements, which is a common treatment for anaemia 
in patients with end-stage CKD, may also promote intestinal 
bacterial growth (35,46). In addition, iron is an essential 
requirement for most microorganisms, and it has been shown 
that iron overload may improve bacterial growth and viru-
lence (47,48).
Some observational studies have shown that haemodial-
ysis patients who are treated with sevelamer show lower ET 
levels, with the consequent decrease in proinflammatory 
cytokines and CRP, and a simultaneous increase in serum 
albumin (43).
Sevelamer may bind non-specifically to negatively charged 
biomolecules, such as portion A of the negatively charged 
lipid of the ET, thus reducing in vitro and in vivo serum con-
centrations. In vitro experiments show that sevelamer binding 
to ET is dose-dependent (49). Sevelamer is known to bind to 
negatively charged bile acids, thus acting as a bile acid 
sequestrant, which may reduce low-density lipoprotein con-
centrations (9).
Several small, short-term studies have shown an associa-
tion between treatment with sevelamer and reductions in ET, 
soluble CD14 and proinflammatory markers, such as CRP and 
IL-6 (34). A recent 8-week randomised crossover study in 
patients with stage 2 to 4 CKD proved that treatment with 
sevelamer carbonate reduces advanced glycation end prod-
ucts (AGE), haemoglobin A1C, and inflammatory biomarkers 
(50). These preliminary data suggest potential benefits of 
sevelamer in reducing proinflammatory cytokines.
b) Sevelamer and cholesterol
Sevelamer binds to negatively charged bile acids, acting as a 
bile acid sequestrant which may reduce low-density lipopro-
tein concentrations (9). The beneficial effects attributed to 
sevelamer on cardiovascular mortality are partly due to the 
hypolipaemic action of the molecule (51). The capacity to 
reduce intestinal cholesterol absorption with sevelamer is 
well-known thanks to several studies which report this effect 
(10, 52). This hypolipaemic effect has been widely described 
in our field. In peritoneal dialysis, sevelamer has been shown 
to reduce phosphorus and cholesterol in a multicentre cross-
over trial conducted in Spain (53). In our field, this effect has 
also led to reduce the need for statins in patients with chronic 
kidney failure (54).
c) Sevelamer and p-Cresol
Among the uremic toxins are those molecules produced by 
the altered intestinal flora in patients with kidney disease. 
The most widely studied toxins are derived from the metab-
olism of aromatic amino acids by this abnormal intestinal 
f lora and which generate molecules such as phenols and 
indoles. These are absorbed into the blood current and con-
stitute uremic toxins with high clinical implications. One of 
these phenols is p-Cresol, a molecule that has proven to have 
an important role in renal function impairment, such as in 
vascular damage in patients with kidney disease (55). The 
binding power of sevelamer in the intestine does not seem to 
be exclusive of dietary phosphorus. Sevelamer has been 
described as a potential absorbent of these molecules of intes-
tinal origin, such as p-Cresol (56). This binding power has 
synthase enzyme, a pathway which could cause vascular dys-
function in patients with kidney disease (31).
b) Klotho
The reduction in FGF23 is accompanied by an increase in 
serum Klotho. These changes are already observed 48 hours 
following treatment. Serum FGF23 and phosphorus decrease 
while sevelamer is used and the increase in Klotho is propor-
tional to the decrease in phosphorus (32).
c) Effect of sevelamer on the WNT-beta-catenin pathway
Olivera et al. examined the effects of phosphorus chelating 
agents, sevelamer hydrochloride and calcium acetate, on 
energy-regulating hormones and WNT-beta-catenin pathway 
in stage 3 to 4 CKD. The study showed that there is an impor-
tant alteration of the WNT pathway in CKD, which is reflected 
by the increased sclerostin and the deregulation of ener-
gy-regulating hormones. Many of these alterations may be 
mitigated by treatment with phosphorus chelating agents, 
although more so with sevelamer hydrochloride than with 
calcium acetate because it significantly decreases serum 
FGF23, sclerostin and leptin and also significantly increases 
alkaline phosphatase levels (33).
2.  Sevelamer and the absorption  
of molecules of intestinal origin
a) Sevelamer and its effect on endotoxins
Haemodialysis patients are characterised by having an 
increased chronic inflammation, which causes a high comor-
bidity that is also increased by a poor nutritional status. 
Endotoxin (ET) is a glycolipid component of the cell wall of 
Gram-negative bacteria that is a powerful stimulus for the 
activation and release of proinflammatory cytokines (for 
example, IL-1, IL-6, and TNF), which adversely affect protein 
metabolism and nutritional status (34). These proinflamma-
tory cytokines are increased in haemodialysis patients and 
have been associated with a higher risk of cardiovascular 
disease, hospitalization and death (35-37). In addition, low 
levels of albumin are associated with increased inflammatory 
markers such as IL6, CRP, TNFD. (38-40).
Cross-sectional observational studies conducted in hae-
modialysis patients have found elevated serum ET levels. 
These are associated with lower serum albumin, an increase 
in proinflammatory cytokines and C-reactive protein, which 
is related to important cardiovascular damage, and, in 
extreme cases, they may even cause septic shock (41). 
Albumin has also proven to have anti-inflammatory proper-
ties by binding to the endotoxin and reducing the expression 
of proinflammatory markers (42,43).
Possible sources of ET include bacterial translocation from 
the gastrointestinal tract (34). In stage 5 CKD, the gastrointes-
tinal barrier function is compromised by oxidative stress, 
circulatory compromise, hypoxia of the intestinal wall, 
reduced motility and bacterial overgrowth (44). Hypoperfusion 
and intestinal oedema induce changes in permeability, facil-
itating bacterial translocation through the gastrointestinal 
lumen towards the blood current (45). The administration of 
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3. Sevelamer, endothelium and inflammation
There is evidence that sevelamer reduces the inflammatory 
status in patients with kidney disease. Chennasamudram et 
al. compared the effects of sevelamer carbonate and calcium 
carbonate on endothelial function (EF) and inflammation in 
peritoneal dialysis (PD) patients with type 2 diabetes mellitus 
(T2DM). EF biomarkers, proinflammatory cytokines, albu-
min, calcium, phosphate and lipids were measured at base-
line and at the end of each treatment. It was observed that 
treatment with sevelamer carbonate has beneficial effects 
compared to calcium carbonate as far as inf lammation 
decrease is concerned, since serum endothelin-1, plasmino-
gen activator inhibitor-1, C-reactive protein and interleukin-6 
levels were reduced. It also significantly improved the lipid 
profile compared to calcium carbonate (71). Navarro et al. 
have equally shown how sevelamer reduces C-reactive pro-
tein, IL-6, endotoxin levels and CD14 concentrations in hae-
modialysis patients, while calcium binders are not capable 
of doing so (72).
All the foregoing effects would be either directly or indi-
rectly involved in the reduction of the inflammatory state. 
Phosphorus has been shown to be a potent inflammatory 
molecule that causes vascular damage (73), so its mere reduc-
tion would entail a decrease. FGF23 and PTH are also proin-
flammatory molecules which have shown their implication 
in vascular damage (74).
Vascular and endothelial inflammation is responsible for 
cardiovascular damage in uremic patients (75). However, as 
has already been described, each molecule involved, whose 
blockage is related to the pleiotropic effects of sevelamer, 
individually shows an association with inflammation. Their 
significance in inflammation, either separately or jointly, 
has not been determined yet. Oxidised LDL cholesterol, bac-
terial endotoxins, AGE and bacterial toxins, such as p-Cresol, 
would increase inf lammatory cell activity and oxida-
tion (76).
4.- Sevelamer and anaemia
Current information about the chelating effects of phospho-
rus on anaemia in patients with CKD is quite scarce. Anaemia 
is another important complication in HD patients, and it is 
associated with a reduced quality of life, higher cardiovascu-
lar morbidity and increased mortality (77, 78, 79).
Aasebø et al. observed that patients who received a higher 
dose of sevelamer showed higher haemoglobin levels than 
those treated with a lower dose, although this association was 
not significant in the multivariate analysis (80).
Ikee et al. studied whether the use of vitamin D, sevelamer 
and cinacalcet analogues affect the capacity of response to 
erythropoiesis-stimulating agents (ESA) in haemodialysis 
patients who are treated with them. Preliminary data showed 
an independent association between the sevelamer dose and 
the capacity of response to ESA in haemodialysis patients. 
The univariate analysis showed a significant association 
between the ESA resistance index and transferrin saturation 
(TSAT) rate, vitamin D analogue dose, and sevelamer dose. In 
been quantified in 10-15% of indoles and 40-50% of p-Cresol 
depending on intestinal pH (57). However, in other studies, 
sevelamer has not proven to reduce the absorption of these 
molecules in CKD rat models (58).
Recently, a study of 57 peritoneal dialysis patients reported 
that patients who were being treated with sevelamer showed 
lower p-Cresol levels. Although it is a cross-sectional obser-
vational study where such an effect cannot be attributed to 
this drug, it would undoubtedly support the evidence pre-
sented by other authors (59).
d) Sevelamer and glycation products
Advanced glycation end products (AGE) are highly inflam-
matory, oxidative and atherogenic molecules formed as a 
result of the oxidation of carbohydrates, lipids and amino 
acids (60). These molecules build up to a greater extent in 
patients with kidney disease, as renal function gets impaired. 
It is known that intestinal absorption of AGE determines AGE 
plasma concentrations (61). Sevelamer reduces intracellular 
and serum levels of AGE in patients with stage 3 to 4 CKD 
with diabetic nephropathy (50) and in diabetic patients on 
dialysis (62). One of these molecules, pentosidine, is reduced 
with sevelamer, but increases with calcium binders (63). A 
recent 8-week randomised crossover study in patients with 
stage 2 to 4 CKD proved that treatment with sevelamer car-
bonate reduces AGE, haemoglobin A1C, and several inflam-
matory biomarkers (50). These preliminary data suggest the 
potential benefits of sevelamer in reducing proinflammatory 
cytokines (50).
e) Sevelamer and uric acid
Uric acid is a molecule which induces oxidative stress and 
endothelial damage in patients with CKD (64). There is con-
troversy about whether or not sevelamer is capable of reduc-
ing serum uric acid levels. Several studies have observed a 
reduction in serum uric acid in haemodialysis (65) and peri-
toneal dialysis (66) patients. Other authors, however, have not 
found this effect (67).
f) Sevelamer and fetuin-A.
Fetuin-A is a glycoprotein that is decreased in situation of 
systemic inflammation (68). Serum fetuin-A levels are lower 
in patients with CKD than in healthy controls, possibly due 
to the presence of inflammation, as suggested by the neg-
ative correlation between fetuin-A and C-reactive pro-
tein (69).
Caglar et al. found that sevelamer has short-term effects 
on fetuin-A levels and consequently on endothelial dysfunc-
tion. In an 8-week randomised prospective study in 50 
patients with stage 4 CKD, the sevelamer effect was compared 
to calcium acetate effect on fetuin-A levels and endothelial 
dysfunction. Fetuin-A levels and flow-mediated dilation were 
determined both at baseline and after treatment. Patients 
with CKD showed significantly lower fetuin-A levels. The use 
of sevelamer led to a significant increase in fetuin-A concen-
tration with dilation improvement, while no significant dif-
ference was observed in the calcium acetate group. In a 
multiple regression analysis, f low-mediated dilation was 
independently related to fetuin-A (70).
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Table 1 – Main studies where Sevelamer has been associated with an improvement in mortality
Study and reference Design Population Outcome or End-point Results
RIND extension
Block et al. 2007 (83) Randomised, open-label clinical 
trial with sevelamer vs. calcium 
chelating agent; for 44 months
127 patients 
Incident HD patients
Primary end-point: to assess 
coronary artery calcification.
Secondary end-point: all-cause 
mortality.
Lower mortality with sevelamer 
(5.3 vs. 10.6 / 100 patients-year, CI 
6.3-14.9) (p = 0.05), multivariate 
analysis (p = 0.016, HR: 3.1, CI 
1.23-7.61).
Suki et al. 2007 (84) Randomised, open-label, 
multicenter study;
sevelamer vs. calcium chelating 
agents 
2103 patients
Prevalent HD patients
All-cause mortality and cause-
specific mortality (cardiovascular, 
infections, etc.).
No significant differences in 
mortality; in > 65 years old, 
sevelamer reduced mortality rate.
Borzecki et al. 2007 (85) Two-year retrospective cohort 
study
1377 patients (sevelamer n = 769, 
calcium carbonate n = 608) 
Incident dialysis patients
Survival comparison between 
both groups
Mortality: 24% vs. 30% 
Non-adjusted HR for death 0.62 
(95% CI 0.50-0.76)-adjusted HR for 
death 0.67 (CI 0.54-0.84). 
DCOR
St Peter et al. (86) Randomised, open-label, 
multicenter study; sevelamer vs. 
calcium chelating agents
Haemodialysis patients End-point: to compare mortality, 
morbidity and hospitalization.
No differences in mortality; 
hospitalization rate (1.7 vs. 1.9 
admissions / patient-year, p 
= 0.02 adjusted) and days of 
hospitalization (12.3 vs. 13.9 days 
/ patient-year, p = 0.03 adjusted) 
lower with sevelamer
Limori [sic: Iimori]  
et al. 2012 (51)
Four-year single-centre cohort 
study
483 patients 
(172 sevelamer and 300 in control 
group) 
Stage 5D CKD
Sevelamer effect on mortality, 
lipid profile and arterial stiffness
General mortality (HR: 0.4, p = 
0.02) and CV mortality (HR 0.29, p 
= 0.03) lower with Sevelamer
INDEPENDENT Study Investigators
Di Iorio et al. 2012 (87) Randomised, multicentre, open-
label, pilot study
Sevelamer vs. calcium carbonate 
for 3 years
239 patients
Stages 3 to 4 CKD
Primary end-point: all-cause 
mortality
Compound end-point: all-cause 
mortality, mortality and start of 
dialysis
With sevelamer, mortality due 
to any cause and compound 
end-point (log-rank test= 11.46, 
p <0.01) were lower than with 
calcium carbonate.
Di Iorio et al. 2013 (88) Randomised, multicentre, 
open-label, controlled study; 
1:1 randomisation to either 
sevelamer or calcium carbonate 
for 2 years
466 patients 
Incident HD patients
Primary end-point: CV mortality 
due to cardiac arrhythmia
With sevelamer, lower CV 
mortality due to arrhythmia (HR, 
0.06, 95% CI, 0.01-0.25, p <0.001); 
all-cause CV mortality and 
mortality due to any cause were 
also reduced.
CV: cardiovascular, CKD: chronic kidney disease, HD: haemodialysis, HR: hazard ratio
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abnormalities, including left ventricular hypertrophy (LVH), 
diastolic dysfunction, aortic stiffness and endothelial dys-
function (92). Animals started treatment with sevelamer after 
6 weeks of CKD induction and were reassessed 8 and 14 weeks 
later. Following the first 8 weeks of treatment with sevelamer, 
mice with chronic kidney failure showed a reduction in serum 
phosphate levels and an improvement in systolic expansion 
of the aortic root, pulse wave velocity and diastolic function; 
LVH remained unchanged. After 6 additional weeks with seve-
lamer, LVH had not progressed. FGF23 levels were not reduced 
until 14 weeks after treatment with sevelamer. In the multiple 
regression analysis, serum phosphate, unlike FGF23, cor-
related independently with left ventricular diastolic function 
and mass. Therefore, sevelamer primarily improved aortic 
stiffness and diastolic dysfunction and secondarily prevented 
LVH development in mice with CKD (82).
Chue et al. raised the hypothesis that the decrease in 
phosphate gastrointestinal absorption with the use of seve-
lamer carbonate would reduce serum levels of phosphaton-
ins such as FGF-23, thus reducing LV mass and arterial 
stiffness, as well as improving LV systolic function and dia-
stolic function in patients with early-stage CKD. For such 
purpose, a randomised, double-blind, placebo-controlled 
study was conducted with 120 patients with stage 3 nondia-
betic CKD. After 40 weeks, no statistically significant differ-
ences were found between sevelamer and placebo with 
respect to the left ventricular mass, systolic and diastolic 
function measured by magnetic resonance imaging, or the 
carotid-femoral pulse wave velocity. This study does not pro-
vide any evidence that sevelamer carbonate improves left 
ventricular mass, LV function, or arterial stiffness in stage 3 
nondiabetic CKD (93).
Cardiovascular protection offered by sevelamer seems to 
be partly due to the reduction in phosphorus absorption, with 
no added calcium, as well as lipid reduction. Calcium-based 
phosphorus chelating agents are commonly used to treat 
hyperphosphataemia; however, it has been observed that they 
increase calcium load, so calcium-free phosphorus chelating 
agents are recommended (94,95). Sevelamer produces a sig-
nificant decrease in serum phosphorus levels without altering 
serum calcium levels, thus causing lower vascular calcifica-
tion rates. In addition, treatment with sevelamer reduces total 
and low-density lipoprotein cholesterol, apolipoprotein B, 
D2-microglobulin and C-reactive protein levels, while increas-
ing high-density lipoprotein levels (96). In this context, Iimori 
et al. examined the effects of sevelamer on mortality, the lipid 
profile and arterial stiffness in patients with stage 5D chronic 
kidney disease. They concluded that a lower mortality in 
patients being treated with sevelamer HCl can be partly 
explained by an improvement in dyslipidaemia and arterial 
stiffness. (97).
The beneficial effect of all binders, except for aluminium, 
in the survival of haemodialysis patients has been recently 
verified by the COSMOS study. It was also observed how seve-
lamer, administered either alone or in combination, improved 
these patients’ survival (98). For years, other authors have 
purported phosphorus control efficacy, with no added cal-
cium or aluminium, to be one of the advantages of sevelamer 
in patients with chronic kidney failure (99).
the multivariate analysis, the sevelamer dose and the TSAT 
turned out to be determining factors independent from the 
ESA resistance index (81).
5.- Clinical implication: Calcification and cardiovascular survival
All the effects described up to now have a direct effect on the 
patient’s clinical situation and are translated into a reduction 
in cardiovascular mortality.
Cardiovascular disease as an important cause of mortality 
in patients with CKD, and hyperphosphataemia seems to be 
one of the most important factors involved. Phosphorus has 
been associated with the development of inflammation and 
atherosclerosis in patients with CKD, as well as in the general 
population with normal renal function, since it favours endo-
thelial dysfunction, increases intima-media thickness, and 
leads to higher cardiovascular mortality (82).
Vascular calcification progression is one of the late mark-
ers of vascular damage; for this reason, its slowdown or dis-
appearance contributes to a longer survival. Coronary artery 
calcification (CAC) is slower in haemodialysis patients treated 
with sevelamer than in those treated with calcium-based 
phosphorus chelating agents (89, 90). This effect is due to sev-
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Conclusion
Sevelamer is a phosphate binder that acts in the intestine, 
preventing absorption without being absorbed. Its use has 
been associated with lower cardiovascular mortality. To a 
great extent, this effect is due to its phosphate-binding capac-
ity and a reduction in its adaptive mechanisms, such as FGF23 
and PTH, and to the fact that it is a calcium-free molecule. 
Over more than 10 years of experience with sevelamer, sev-
eral effects derived from its capacity to bind other molecules 
in the intestine, which are important for the reduction in car-
diovascular risk, have been demonstrated. The reduction in 
LDL cholesterol, AGE, phenols, uric acid or endotoxins, all of 
which are of intestinal origin, seems to have an effect on the 
reduction in the inflammatory status and oxidation of these 
patients. All these actions have significant effects on concrete 
clinical aspects, such as anaemia, vascular calcification, ath-
erogenesis and endothelial dysfunction, all of which result in 
improved survival of patients with CKD.
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